| Literature DB >> 20097046 |
Florian Seemüller1, Michael Riedel, Michael Obermeier, Michael Bauer, Mazda Adli, Klaus Kronmüller, Florian Holsboer, Peter Brieger, Gerd Laux, Wolfram Bender, Isabella Heuser, Joachim Zeiler, Wolfgang Gaebel, Eva Dichgans, Roland Bottländer, Richard Musil, Hans-Jürgen Möller.
Abstract
Due to strict exclusion criteria the generalizability of randomized controlled trials appears to be limited. Therefore, outcomes of naturalistically treated depressive inpatients with respect to depression mean scores, response and remission rates were evaluated. This was a multicenter trial, conducted in 12 psychiatric hospitals in Germany with a follow-up period of 4years. Patients were assessed biweekly from admission to discharge with diverse psychopathological rating scales. All patients (n=1014) met DSM-IV criteria for major depressive episode. Results are presented only for the acute inpatient treatment period. Mean inpatient treatment duration was 53.6+/-47.5days. Reduction on depression scales was evident as soon as week 2 and remained significant. Mean HAMD-17 total score decreased from 22.3 to 8.8. A total of 68.9% were classified as responders (> or =50% reduction of the initial HAMD-17 score), whereas 51.9% achieved remission (HAMD-17 total score < or =7). Of those who ultimately achieved response more than 40% did so within the first 2weeks. An individualized naturalistic inpatient treatment approach appears to be beneficial in terms of effectiveness. 2009 Elsevier B.V. and ECNP. All rights reserved.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20097046 DOI: 10.1016/j.euroneuro.2009.11.011
Source DB: PubMed Journal: Eur Neuropsychopharmacol ISSN: 0924-977X Impact factor: 4.600